Lopid Indication:

For the treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy also used in Tourette's syndrome and Severe hyperactivity.

Lopid Mechanism Of Action:

The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known. Its effect on the central nervous system is thought to be associated with the competitive blockade of postsynaptic dopamine D2 receptors in the mesolimbic dopaminergic system and an increased turnover rate of brain dopamine.

Lopid Drug Interactions:

Anisotropine Methylbromide The anticholinergic increases the risk of psychosis and tardive dyskinesia
Atropine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Belladona The anticholinergic increases the risk of psychosis and tardive dyskinesia
Benztropine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Biperiden The anticholinergic increases the risk of psychosis and tardive dyskinesia
Clidinium The anticholinergic increases the risk of psychosis and tardive dyskinesia
Dicyclomine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Ethopropazine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Glycopyrrolate The anticholinergic increases the risk of psychosis and tardive dyskinesia
Homatropine Methylbromide The anticholinergic increases the risk of psychosis and tardive dyskinesia
Hyoscyamine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Isopropamide The anticholinergic increases the risk of psychosis and tardive dyskinesia
Methantheline The anticholinergic increases the risk of psychosis and tardive dyskinesia
Mepenzolate The anticholinergic increases the risk of psychosis and tardive dyskinesia
Orphenadrine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Oxyphencyclimine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Procyclidine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Propantheline The anticholinergic increases the risk of psychosis and tardive dyskinesia
Trihexyphenidyl The anticholinergic increases the risk of psychosis and tardive dyskinesia
Tridihexethyl The anticholinergic increases the risk of psychosis and tardive dyskinesia
Scopolamine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Thioridazine Increased risk of cardiotoxicity and arrhythmias
Mesoridazine Increased risk of cardiotoxicity and arrhythmias
Rifampin The rifamycin decreases the effect of haloperidol
Rifabutin The rifamycin decreases the effect of haloperidol
Propranolol Increased effect of both drugs
Methyldopa Methyldopa increases haloperidol effect or risk of psychosis
Lithium Possible extrapyramidal effects and neurotoxicity with this combination
Ketoconazole The imidazole increases the effect and toxicity of haloperidol
Itraconazole The imidazole increases the effect and toxicity of haloperidol
Fluconazole The imidazole increases the effect and toxicity of haloperidol
Clozapine Clozapine increases the effect and toxicity of haloperidol
Guanethidine The agent decreases the effect of guanethidine
Atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
Carbamazepine Carbamazepine decreases the effect of haloperidol

Lopid Food Interactions:

Take with food to reduce irritation, limit caffeine intake. Avoid alcohol.

Lopid Generic Name:

Synonyms:

  • Not Available

Drug Type:

Small Molecule; Approved

Absorption:

Oral-60%

Toxicity (Overdose):

LD50=165 mg/kg (rats, oral)

Protein Binding:

92%

Biotransformation:

Hepatic

Half Life:

3 weeks

Dosage Forms of Lopid:

Liquid Oral
Tablet Oral
Solution Oral
Liquid Intramuscular

Chemical IUPAC Name:

4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one

Organisms Affected:

Humans and other mammals

Lopid to general, pharmacology

General, pharmacology..
Cholesterol